Clinical Trial Update: Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma [Phase 2]

View source ↗

Summary

Phase 2 trial of NGR-hTNF as a single agent in advanced or metastatic malignant pleural mesothelioma completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• NGR-hTNF (NGR-hTNF)

Snippet

Sponsor: AGC Biologics S.p.A. | Conditions: Malignant Pleural Mesothelioma | Phase 2 | Status: COMPLETED